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Summary
The identification of new risk factors for specific diseases is
an enduring theme in medical research. Advances in molecu-
lar biology, genetics, and computational biology are accelerat-
ing the pace of this work. The research seeks to increase our
understanding of the causes of diseases, but there is also
hope that the recognition of new risk factors will lead to im-
proved methods for identifying persons who are in the early
stages of, or at high risk for, the diseases of concern. Re-
search has shown, however, that a genomic biomarker must
have a much stronger association with the disease outcome
than we ordinarily see in etiologic research if it is to provide a
basis for early diagnosis or prediction in individual patients.
However, even if the literature contains ~150,000 reports of
disease-associated molecular markers, there are still very few
validated biomarkers of proven and robust clinical utility. At
present there is no established, standardized means for vali-
dating the association between a marker (or set of markers)
and clinical outcomes. The Regulatory Authorities have un-
dertaken a number of initiatives in order to enhance the use of
biomarkers in drug development, to promote a more informed
drug development and maximise the benefit of innovative
medicines to the patients.
KEY WORDS: genetic testing, Genomic Biomarkers (GBs), validation, quali-
fication, regulation, pharmacogenomics.
Introduction
Genetic testing is a type of medical test that identifies changes
in chromosomes, genes, or proteins. Most of the time, testing
is used to find changes that are associated with inherited disor-
ders. The results of a genetic test can confirm or rule out a sus-
pected genetic condition or help determine a person’s chance
of developing or passing on a genetic disorder. Several hun-
dred genetic tests are currently in use, and more are being de-
veloped.
The rapidly expanding knowledge of disease pathogenesis at
the molecular level is providing new targets for disease charac-
terization, early diagnosis, and drug discovery and develop-
ment. Several decades of intensive research have originated
multiple factors or biomarkers that are likely to be helpful in the
diagnosis, characterization, and therapy selection. A deep un-
derstanding of the relative relevance of each biomarker will be
key to efficiently diagnose diseases, adverse drug responses
and direct our patients towards the drugs more likely to be of
benefit based on their particular profile. The development of
new preclinical models is of paramount importance to achieve
these goals. There is an enormous effort to identify, character-
ize, and validate meaningful biomarkers because its successful
development will represent a step forward in the individualiza-
tion of diagnosis, therapy and monitoring. Advances in meth-
ods and technology now enable construction of a comprehen-
sive biomarker pipeline from six essential process components:
candidate discovery, qualification, verification, research assay
optimization, biomarker validation and commercialization. To
accommodate for a swift regulatory appraisal of these new
technologies in the processes of drug development and ap-
proval, the European Medicines Agency has put in place dedi-
cated experts panels, new procedures.
Genetic testing and genomic biomarkers
It is important to distinguish between genetic testing for the di-
agnosis and prognosis of disease and genetic test performed
for pharmacogenomics purposes (Table I). 
In the first case, the test is carried out to identify causative
gene mutations or polymorphisms of susceptibility while in the
second case the genetic test will reveal DNA and RNA charac-
teristics as related to drug responses. Historically, successful
genetic markers have been linked to single effects for both the
patient and the patient’s family (e.g. cystic fibrosis testing,
spinal muscular atrophy testing etc.) and/or to monitor particu-
lar effects on large populations (i.e. HIV mRNA, HCV mRNA
etc.). In this context, genetic testing should be described as a
particular assay to detect:
– a particular genetic variant (or set of variants)
– for a particular disease
– in a particular population
– for a particular purpose.
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Rapid advances in research are leading to growing knowledge
about the genetics and, thus, to an expanding array of genetic
markers which may be useful not only for more accurate diag-
nosis but also for better therapeutic interventions. In the con-
text of drug development, the traditional approach to genetic
testing needs to be expanded because: 
a) it is at odds with goals for individualized therapy;
b) does not recognize multidimensional quality of clinical re-
sponse; 
c) does not include possibility of multiple biomarkers providing
useful information in aggregate. 
Therefore, recently, regulatory agencies (CHMP/ICH/437986/
2006) introduced the concept of “Genomic Biomarker” (GB)
which is defined as a DNA or RNA characteristic that is an indi-
cator of normal biologic processes, pathogenic processes,
and/or response to therapeutic or other intervention. Therefore,
a genomic biomarker should reflect:
• The expression of a gene
• The function of a gene
• The regulation of a gene.
DNA characteristics include, but are not limited to:
• Single nucleotide polymorphisms (SNPs)
• Variability of short sequence repeats
• DNA modification, e.g. methylation
• Insertions
• Deletions
• Copy number variation
• Cytogenetic rearrangements, e.g. translocations, duplica-
tions, deletions or inversions.
RNA characteristics include, but are not limited to:
• RNA sequence
• RNA expression levels
• RNA processing, e.g. splicing and editing
• MicroRNA levels.
Robust, reproducible accessible genomic biomarkers are of di-
agnostic value, and may lead to identification of causal factors.
They therefore can be used clinically to screen for diagnose, to
monitor the activity of diseases, and also may be useful to
guide molecularly targeted therapy and personalised regimens
or to assess therapeutic response. 
The importance and the potential utility of GB has been recog-
nized by substantial public and private funding, and GB discov-
ery efforts are now commonplace in both academic and indus-
trial settings. 
For years GBs have been used to test for single gene muta-
tions predisposing to disease. Examples of these include famil-
ial hypercholesterolemia and mutations in LDL receptors (1),
high blood pressure, hyperkalemia and mutations in WNK ki-
nase genes (2) and many other monogenic disorders (3). How-
ever, while GBs give diagnosis, causality and pathophysiology
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Table I - Classification of genetic tests according to their purpose*.
Population screening Conducted to identify asymptomatic individuals from within a particular community or a subsection of
that community who have an increased chance of having a specific genetic disorder, of carrying a spe-
cific genetic predisposition to disease or of being a carrier of a recessive genetic variant. For example,
women may be tested for BRCA1&2 - genes associated with breast cancer, so that preventative mea-
sures and early intervention can be considered.
Diagnostic testing These tests are conducted to confirm or rule out a known or suspected genetic disorder in a sympto-
matic individual. For example, genetic testing is often used to confirm the clinical diagnosis of cystic fi-
brosis (CF).
Predictive testing These tests are conducted to determine the probability of asymptomatic individuals who are suspected
of having an inherited disorder developing the clinical manifestations.
Carrier testing Conducted to determine if an individual is a “carrier” of a gene for an autosomal recessive or X-linked
genetic disorder. For example, couples undergo carrier testing for disorders such as Tay-Sachs dis-
ease, to assist in their reproductive decisions.
Prenatal testing Conducted during pregnancy to determine whether there is an increased risk of having a child with a ge-
netic disorder. Down’s Syndrome is the most common genetic disease screened by this method.
Newborn screening These tests focus on the identification of metabolic disorders in newborns. Early detection and treat-
ment may be crucial to reduce the progression of such diseases. One example is the newborn screen-
ing for phenylketonuria (PKU).
Pre-symptomatic testing These tests are conducted on healthy individuals to determine whether or not they carry a genetic muta-
tion that increases their likelihood of developing late-onset diseases and disorders. Examples include
Huntington’s disease and Alzheimer’s disease.
Susceptibility (or predisposition) These tests are conducted to determine the risk or probability that individuals with the genetic variant
testing will develop a particular disease.
Pharmacogenetic testing Conducted to determine individual genetic variability impact on drug efficacy and toxicity.
Forensic/Identity testing These tests are conducted to discover genetic linkages in criminal investigations between suspects and
evidence or between children and their biological parents.
* Modified from OECD (DSTI/STP/BIO 2006)17.
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information in monogenic disorders, they seem to have a
scarce or no detectable impact on polygenic and complex dis-
orders. Complex disorders are caused by multiple genetic and
environmental factors, are characterized by high population
prevalence, lack of clear Mendelian patterns of transmission,
etiologic and phenotypic heterogeneity, and are involved in a
continuum between disease and non disease states. Another
complicating factor in developing biomarkers for complex traits
is the difficulty in understanding the role these genetic factors
play in the pathophysiology of disease.
The identification of “key” genes influencing complex traits
such as heart disease, diabetes, and cancer will not only assist
in predicting those individuals who are predisposed to disease,
but may potentially have significant impact on the pharmaceuti-
cal industry as the identification of GBs for disease susceptibili-
ty may lead to new targets, better classification of disease and
more informed clinical development.
A major challenge facing the development of GBs for complex
diseases, is in the etiologic or phenotypic heterogeneity of the
clinical conditions. Heterogeneity influences the ability both to
discover a biomarker and to prove the clinical utility of the bio-
marker once identified. Clearly, a biomarker that is specifically
associated with the phenotype of interest has more clinical utili-
ty than one associated with a range of phenotypes. 
Following an understanding of the relationship between the
identified biomarker and the phenotype, all additional polymor-
phisms in the gene or its regulatory region and their relation-
ship to the observed functional effect should be investigated.
This phase of investigation often includes studies in a variety of
populations, as a specific polymorphism may have utility in one
but not in another. 
GBs are frequently evaluated in relation to drug development
in order to accumulate information on their ability to help re-
fining treatment effects, in terms of efficacy and/or adverse
drug reactions (4-7). The most common application of genetic
markers in drug development and medicine today is the
genotyping of the drug metabolism enzymes. The genetic
polymorphisms in these enzymes do not predict disease or
response to therapy but lead to differences between individu-
als in metabolic activity and clearance of drugs and therefore
in the overall exposure of patients to the compound. The drug
metabolizing enzymes are not targets for new therapeutics
but rather may guide dosing regimen alterations for therapeu-
tics metabolized by the polymorphic enzyme. Even though
these tests are not widely used outside of clinical trials, there
is growing acceptance of using such GBs in determining
proper dosing regimens.
In addition individual’s clinical response to treatment may be in-
fluenced by genetic variants in the coding or regulatory regions
of genes involved in the therapeutic pathways. New biomarkers
that identify incipient damage that leads to preclinical and clini-
cal toxicities will enable better decision-making during drug de-
velopment and clinical management of patients. In the case of
genetic predisposition to a drug adverse reaction caused by a
specific drug in a small number of individuals, identification of
the responsible genetic variants may prevent exposure to pa-
tients at risk of an adverse reaction while enabling the success-
ful use of a drug to the many who would benefit. Therefore, ge-
netic biomarkers for response may facilitate classification of in-
dividuals by response, improving therapeutic outcome, and
personalizing prescriptions. 
Some examples of GBs associated to drug response include: 
• UGT1A1 in the irinotecan therapy in patients with colon can-
cer (8-11)
• CYP2C9/VKORC1 impact on the warfarin dosing in patients
in anticoagulant treatment (12-15) 
• HLA-B*5701 and abacavir hypersensitivity syndrome (16-18) 
• EGFR status and Erbitux (19-22)
• Her2/neu status and Herceptin (23-26)
• Philadelphia chromosome (~ Bcr-abl) and Gleevec (27, 28).
Already there are over 50 drugs that mention the possibility to
test biomarkers in their labels. The expectation is that the next
few years will see a rapid increase in the number of drugs ap-
proved with GB data in their labels, and older drugs that will
have GBs data added to their labels.
Despite the presence and promise of a growing body of re-
search relating GB to treatments effects, in addition to the still
unveiled complexities of genomic interactions and regulation,
numerous barriers exist to a widely use of GB in the clinic of
complex diseases. Lack of sufficient evidence for consistent
phenotype-genotype associations, lack of evidence to support
generalizability to diverse populations, significant overlap be-
tween genotypes and measurable disease, influence of poly-
genic factors, difficulty in defining the true clinical phenotype
and lack of quality assured, cost-effective and feasible labora-
tory technologies have all been considerable hurdles in this
process together with the lack of algorithms available to the
physicians for an informed choice among the available thera-
peutic options to be tailored to the specific characteristics of
the patients and of their condition. 
Therefore, prior to widespread clinical application of a GB, mul-
tiple scientific and clinical studies must be completed to char-
acterize the genetic variants and delineate their functional sig-
nificance in the pathophysiology of a carefully defined pheno-
type and to develop the tools needed for their clinical use.
Biomarkers validation and qualification
Increased knowledge of genes biology is generating promising
marker candidates for more accurate diagnosis, prognosis as-
sessment, and therapeutic targeting. To apply these exciting re-
sults to maximize patient benefit, a disciplined application of
well-designed clinical trials for assessing the utility of markers
should be used. Clinical trial designs for evaluating the useful-
ness of molecular traits or markers within the context of genetic
testing are fundamentals. Ideally, the population studied should
be one in which knowledge of the marker would have substan-
tial clinical relevance and where the feasibility of obtaining ap-
propriate specimens is established. Although biomarkers are
emerging as key indices for individualized patient management,
oversight and regulation of their safety and validity have lagged.
About 1,000 biomarkers are available as diagnostic tests, al-
most universally marketed as home-brew tests without formal
approval from regulatory agencies. Although biomarkers have
been used in decision-making, clinical practice, drug develop-
ment and regulatory evaluation of new drugs for many years,
there is currently an increased focus on them as a means to fa-
cilitate and expedite regulatory decision-making (29).
There are numerous potential biomarkers that could be related to
different clinical events or processes, highlighting the need for
consensus among investigators and regulators on the basic prin-
ciples of validating and qualifying biomarkers for decision-making. 
In order to provide a forum for informal discussion the regula-
tors both at EU level (European Medicines Agency – EMEA)
and at US level (Food and Drug Administration – FDA) since
2003 have established special experts panel (The Pharma-
cogenomics Working Party – PGWP) and the Interdisciplinary
Pharmacogenomic Review Group – IPRG) able to initiate the
reflection on the implication of the use of genomic biomarkers
in the development of medicinal products. These two expert
committees were able to discuss with Industry data submitted
on a voluntary basis, including genomic and non-genomic bio-
markers and spanning from analytical platforms validation stud-
ies, toxicology testing, clinical development designs. 
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The relevance of the biomarkers in clinical development has
been recently re-emphasized in the Final Report of the
EMEA/CHMP think-tank on innovative drug development (Inno-
vative drug development approaches (EMEA/127318/2007 -
http://www.emea.europa.eu/pdfs/human/itf/12731807en.pdf): 
“Use of biomarkers in early non-clinical and clinical develop-
ment to provide a more informed scientific basis for the design
of pivotal trials has already proven useful in streamlining the
development of targeted therapies. The identification and vali-
dation of predictive efficacy and safety biomarkers in particular
could be very important in future drug development as changes
in biomarkers following treatment may reflect the pharmacody-
namic/clinical response to the product”.
A research plan should include assay validation and biomarker
qualification. Method of validation has been the object of the
FDA “Guidance for Industry on Bioanalytical Method Valida-
tion” (2001). Anyway there is a little regulatory rules on valida-
tion of biomarkers assays. Method validation should demon-
strate that a particular assay is reliable for the intended appli-
cation (29) and thus the rigor of method validation increases
from the initial validation proposed for exploratory purposes, to
the more advanced validation for a biomarker and the use of
results. Different applications of biomarkers require targeted
method validation. Validation of candidate biomarkers is typi-
cally achieved through the use of independent sample cohorts.
This is essentially replication of results in different sample pop-
ulations. Many studies today are performed on both a training
cohort to identify susceptibility loci and a validation cohort to
replicate and validate the results, both within the scope of the
same investigation. These replication studies can be difficult
because of the complexity involved in controlling environmental
factors between different populations. Thus, true correlates that
could contribute to disease in one population may not replicate
in another population that was subject to a uniquely different
environment. In contrast to validation, the biomarker qualifica-
tion focuses on evidence linking a biomarker with disease biol-
ogy and as appropriate with clinical end points (29). 
All the above taken in to account, we think that biomarker de-
velopment and use should be guided by the pragmatic principle
of being linked to how they will be used in terms of context
(e.g., in the context of non-clinical toxicology) and purpose
(e.g., in the same context-detection of acute drug-induced in-
jury). A biomarker research plan is a graded process. Moving
from an initial exploratory approach, often retrospective, a key
feature of a biomarker development plan is that it prospectively
describes the studies required for its qualification. 
Biomarkers that will be used as surrogate endpoints (SEPs) in
clinical efficacy trials or as markers of toxicity will require sub-
stantial qualification, partly because it is not self-evident what
relationship exists between the effects of the drug on the bio-
marker and the effects of the drug on outcomes, and partly be-
cause the consequences of unreliable SEPs or toxicity bio-
markers, in terms of regulatory decision-making, are much
graver. Two conditions, if simultaneously true, would be suffi-
cient to accept an SEP (30): (a) the SEP (biomarker) must be
correlated with the clinical endpoint; and (b) the marker must
fully capture the net effect of the intervention on the clinical effi-
cacy end point. However, it is clear from regulatory guidance
and the history of clinical practice that SEPs and toxicity bio-
markers cannot be qualified on theoretical grounds alone, but
must be based upon objective data. Moreover, to ensure their
robustness, the data should originate from multiple studies by
different investigators. All these are practical arguments for a
collaborative framework for the development of biomarkers. In-
deed a collaboration permit to avoid the duplicative efforts and
to enable cost-sharing, joint solutions to legal issues, intellectu-
al property. It was for these reasons that the Pharmaceutical
Research and Manufacturers of America entered discussions
with FDA in 2004 with a view to creating a consortium for the
qualification of biomarkers for regulatory decision-making. The
Pharmaceutical Research and Manufacturers of America/FDA
Biomarker Consortium is set up with the Foundation for the Na-
tional Institutes of Health and launched formally in October
2006. The consortium will manage biomarker projects to en-
sure scientific rigor, appropriate prioritization and funding, and
compliance with relevant laws. 
In parallel the Regulatory Authorities at international level (the
European Medicines Evaluation Agency – EMEA, the US Food
and Drug Administration – FDA) have initiated new regulatory
processes aiming at providing scientific advice both for the de-
velopment of novel biomarkers and for their use in the drug de-
velopment context as acceptable regulatory standards (bio-
markers qualification). It is also worth mentioning that in De-
cember 2007, the EU Parliament and Council agreed – within
the Research Framework Program 7 – FP7 – on the Innovative
Medicines Initiative (IMI), which is aiming at establishing solid
public-private partnerships to enhance the establishment of the
collaborative framework needed to promote innovative devel-
opment approaches in the pharmaceutical sector, inter alia the
development of biomarkers. 
Personalized medicine and biomarkers
Most patient populations show large inter-individual variability
in drug response and toxicity. Individuals may have excellent
responses, respond partially, or experience adverse drug re-
actions to standard doses (4-7). This individual variation can
be due to genetic, physiological, pathophysiological, or envi-
ronmental factors. A drug’s absorption, distribution and metab-
olism, and interactions with its target can be determined by
genetic differences. Genetic factors account for 15% to 30%
of differences in drug metabolism and response between indi-
viduals. For some drugs or classes of drugs, genetic factors
can account for up to 95% of inter-individual variability in drug
disposition and effects. Potential GB may be in genes involved
with the drug target, the metabolism of the drug, or in the dis-
ease pathway (4). The ability to identify GB corresponding to a
therapeutic effect is the basis for the concept of the so-called
personalized medicine (31). Personalized medicine can be de-
fined as a specific and selected algorithm addressed to a par-
ticular patient to optimize treatment to maximize efficacy and
minimize risk, based on the genetic make-up of the patient
(31). The develop of a personalized medicine is closely linked
to GB, which may serve as the basis for diagnosis, drug dis-
covery and monitoring of diseases. New molecular technolo-
gies and new biomarker development processes have
emerged over the few years towards this goal. However, a
complete agreement on processes to qualify new GBs for de-
veloping novel prognostic biomarkers for a possible personal-
ized medicine is lacking. In prostate cancer, for example, the
prostate-specific antigen (PSA) changes is an accepted pre-
clinical biomarker, but this marker is far from perfect in terms
of specificity and sensitivity. Several new potential GBs with
potentially better specificity and sensitivity than PSA have
been discovered and published. These include specific gene
mutations (e.g., HPC1, RNase-L) and combined single nu-
cleotides polymorphisms (SNPs) located within five chromoso-
mal regions (32). However, these new genomic biomarkers
have a mechanistic importance but a scarce clinical utility
since are unable to distinguish between indolent and aggres-
sive prostate cancer. Other examples concern the colorectal
cancer that is the second leading cause of cancer-related
death. Current clinical practice in colorectal cancer screening
(fecal occult blood test, FOBT; colonoscopy) has contributed
to a reduction of mortality. However, despite these screening
152 Clinical Cases in Mineral and Bone Metabolism 2008; 5(2): 149-154
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programs, about 70% of carcinomas are detected at advanced
tumor stages (UICC III/IV) presenting poor patient prognosis.
Thus, innovative tools and methodologies for early cancer de-
tection can directly result in improving patient survival rates.
Biomedical research has advanced rapidly in recent years with
the availability of technologies such as global gene and pro-
tein expression profiling. We developed a low density home-
made oligoarray (“AndroChip 2”) containing 190 genes, select-
ed on the basis of their proved or potential role in prostate
cancerogenesis related to androgen signalling (33, 34). This
array was successfully utilized to monitor the gene expression
profiles in androgen-dependent and androgen-independent
cells for pharmacogenomic purposes. Multiple genes were
identified exhibiting differential expression during drug treat-
ment. Importantly, we recently demonstrated that all genes
fixed on the “Androchip 2” show a detectable expression lev-
els in peripheral blood cells (PBMC). Therefore, “Androchip 2”
may be helpful in developing novel prognostic biomarkers and
therapy for androgen-sensitive and androgen-refractory
prostate cancer. PBMC represents an attractive, clinically ac-
cessible tissue for the identification of novel biomarkers. In
fact, circulating blood cells come into contact with every cell in
the human body and provide an active defence against insult
and injury. This peculiarity, combined with the fast turnover
rate of blood cells, gives rise to the possibility that subtle
changes occurring in association with injury or disease within
the cells and tissues of the body may trigger specific changes
in gene expression at a micro-level within the blood cells.
These changes can capitalized on as biosensors for diagnos-
tics purposes. An increasing number of clinical pharmacoge-
nomic (PG) studies are employing gene expression profiling
PBMCs for the identification of novel transcriptional biomark-
ers of disease, drug activity, drug efficacy/toxicity, and even
markers predictive of clinical outcomes. Comprehensive tumor
profiling has become a field of intensive research aiming at
identifying biomarkers relevant for improved diagnostics and
therapeutics (35). A major challenge in development of cancer
biomarkers will be the integration of proteomics with genomics
and metabolomics data and their functional interpretation in
conjunction with clinical data and epidemiology. Proteomics-
based technologies enable to distinguish the healthy patient
from the tumor patient with high sensitivity and specificity and
could greatly improve common classification systems and di-
agnostics. However, this progress has not yet been trans-
ferred from bench to bedside but could open the door to a
more accurate and target specific personalized medicine with
improved patient survival (36). 
Conclusions
This paper follows the broad definition of a genomic biomarker
as a characteristic that can be objectively measured and eval-
uated as an indicator of normal biological or pathogenic
processes as well as pharmacological responses to a thera-
peutic intervention. Tests based on “classical” biomarkers
have been around for more than half a century, but interest in
their application for diagnostics and drug discovery as well as
development has increased remarkably since the beginning of
the 21st century with the discovery of GBs. GBs are different
types of biomarkers originating from various “-omics” technolo-
gies and combining genomics, proteomics and metabolomics.
Currently the most important applications of GBs are in drug
discovery and development. The role of GBs in various thera-
peutic areas particularly cancer, cardiovascular diseases and
disorders of the central nervous system, is expected to
change in the near future the modern medicine. In fact, GBs
are useful not only for diagnosis of some of these diseases
but also for understanding the pathomechanism as well as a
basis for development of therapeutics. GBs will facilitate the
combination of therapeutics with diagnostics through pharma-
cogenetics, pharmacogenomics and pharmacoproteomics,
and will thus play an important role in the development of per-
sonalized medicine. The Regulatory Authorities in Europe and
in US have already open the dialogue with the stakeholders to
ensure that the benefits of the new technologies are conveyed
in a timely manner to patients with the provisions of better in-
formation on the use of both old and innovative medicines.
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